Abstract
Antimicrobial hybrids are compounds that can inhibit, stop the growth of, or kill microorganisms, including bacteria, fungi, and parasites. Antibiotics, a subset of antimicrobial agents, specifically target bacteria and include well-established classes such as β-lactams, macrolides, quinolones, and oxazolidinones. Other antimicrobial hybrids are designed for treating a wide range of diseases, including fungal infections, leishmaniasis, parasitic diseases (such as trypanosomiasis and malaria), leprosy, and tuberculosis. Some hybrids are designed to treat a variety of diseases. This review highlights studies primarily published between 2000 and 2023, with a few from 2024, underscoring the dynamic and rapidly evolving nature of antimicrobial hybrid research.
| Original language | English |
|---|---|
| Journal | Current Medicinal Chemistry |
| Early online date | 4 Aug 2025 |
| DOIs | |
| State | E-pub ahead of print - 4 Aug 2025 |
Bibliographical note
Publisher Copyright:Bentham Science Publishers
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hybrids
- antibiotic
- antimicrobial
- fungal infections
- leishmaniasis
- leprosy
- malaria
- parasitic infections
- trypanosomiasis
Fingerprint
Dive into the research topics of 'Hybrids/Conjugates/Chimera Drugs-Antimicrobial Hybrids: Antibiotics, Antifungals, Antituberculars, Antimalarials'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver